Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial

Diabetes, Obesity and Metabolism

Volumn 17, Issue 10, 2015, Pages 949-955

  Florez, H ^a   Reaven, P D ^b   Bahn, G ^c   Moritz, T ^c   Warren, S ^d   Marks, J ^a   Reda, D ^c   Duckworth, W ^b   Abraira, C ^a   Hayward, R ^e   Emanuele, N ^c  

^a UNIVERSITY OF MIAMI   (United States)

^b Phoenix VA Health Care Center   (United States)

^c HINES VA HOSPITAL   (United States)

^d University of New Mexico   (United States)

^e VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Cardiovascular disease; Older adults; Rosiglitazone; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLYCEMIC CONTROL; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RISK ASSESSMENT; SURVIVAL RATE; VETERANS HEALTH; AGED; ANALYSIS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; GOVERNMENT; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR; UNITED STATES;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; THIAZOLIDINEDIONES; TIME FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84942292900     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12487     Document Type: Article

References (24)

1. Dormandy JA, Charbonnel B, Eckland DJA etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
2. Saremi A, Schwenke DC, Buchanan TA etal. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 393-399.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
4. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136.
5. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195.
6. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147: 578-581.
7. Home PD, Pocock SJ, Beck-Nielsen H etal. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357: 28-38.
8. Home PD, Pocock SJ, Beck-Nielsen H etal. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
9. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm. Accessed 4 November 2014.
10. Nesto RW, Bell D, Bonow RO etal. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-263.
11. Baba T, Shimada K, Neugebauer S etal. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 2001; 24: 953-954.
12. Abraira C, Duckworth W, McCarren M etal. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003; 17: 314-322.
13. Duckworth W, Abraira C, Moritz T etal. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
14. Koro CE, Bowlin SJ, Weiss SR. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf 2005; 14: 697-703.
15. Bach RG, Brooks MM, Lombardero M etal. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2013; 128: 785-794.
16. Simon D. Rosiglitazone. Prim Care Diabetes 2009; 3: 123-124.
17. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
18. Meneghini LF, Florez H, Tamariz L. The Avandia debacle: methodology and practical importance of the findings. South Med J 2007; 100: 1062-1063.
19. Nathan DM. Rosiglitazone and cardiotoxicity-weighing the evidence. N Engl J Med 2007; 357: 64-66.
20. Nathan DM, Buse JB, Davidson MB etal. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
21. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S1-201.
22. Kahn SE, Haffner SM, Heise MA etal. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
23. Khanderia U, Pop-Busui R, Eagle KA. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 2008; 42: 1466-1474.
24. Valencia WM, Florez H. Pharmacological treatment of diabetes in older people. Diabetes Obes Metab 2014; 16: 1192-1203.